Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16451085 | 1.00 | ATM (0.38) | ATM | |
| SCHEMBL16451090 | 1.00 | ATM (0.38) | ATM | |
| SCHEMBL16451091 | 0.88 | ATM (0.36) | ATM | |
| SCHEMBL14210445 | 0.88 | ATM (0.36) | ATM | |
| SCHEMBL16451092 | 0.88 | ATM (0.36) | ATM | |
| SCHEMBL9611082 | 0.86 | ATM (0.32) | ATM | |
| SCHEMBL22930451 | 0.83 | CHRM3 (0.36) | — | |
| SCHEMBL19497556 | 0.83 | ATM (0.36) | ATM | |
| SCHEMBL9611092 | 0.81 | ATM (0.48) | ATM | |
| SCHEMBL22959705 | 0.80 | ATM (0.34) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MITOTHERAPEUTIX LLC | 2022-06-09 | — | — | US | disclosed |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-11 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170326250-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-11-16 | — | — | US | disclosed |
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8329908-B2 | Dual action antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820823-B2 | Dual action antibiotics | Morphochem Aktiengesellschaft Fur Kominatorische Chemi (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ATM 4052/4885 |
| US-20170326250-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | ATM 3755/4885 |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | ATM 1700/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | ATM 1521/4885 |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | ATIC, PCNA, FOLR1 | ATM 4058/4885 |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | ATM 1700/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | ATM 1700/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ATM 4052/4885 |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | ATM 1521/4885 |
| US-20110059946-A1 | DUAL ACTION ANTIBIOTICS | SLC11A2, MRPL21, MAP2K5 | ATM 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.